ERBB2 and breast cancer: Overall, the combination of PI3K inhibitors and HER2-targeted therapy represents a rational and targeted therapeutic approach for HER2+ BC, addressing co-activation of PI3K signaling pathways, overcoming resistance mechanisms, and exerting antitumor efficacy offers the possibility of strengthening.